{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:13:25Z","timestamp":1740107605664,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005592","name":"Center for the Study of the American South, University of North Carolina, Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abbott"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00592-019-01409-3","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T05:48:27Z","timestamp":1567230507000},"page":"229-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries"],"prefix":"10.1007","volume":"57","author":[{"name":"for the DPV and DIVE registry initiatives","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gesine","family":"van Mark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J\u00fcrgen","family":"Wosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Plaumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sziegoleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"1409_CR1","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669\u20132701. \nhttps:\/\/doi.org\/10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"key":"1409_CR2","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes A","year":"2019","unstructured":"American Diabetes A (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:S90\u2013S102. \nhttps:\/\/doi.org\/10.2337\/dc19-S009","journal-title":"Diabetes Care"},{"key":"1409_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamainternmed.2014.2894","volume":"174","author":"S Vijan","year":"2014","unstructured":"Vijan S, Sussman JB, Yudkin JS, Hayward RA (2014) Effect of patients\u2019 risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174:1227\u20131234. \nhttps:\/\/doi.org\/10.1001\/jamainternmed.2014.2894","journal-title":"JAMA Intern Med"},{"key":"1409_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1055\/s-0033-1343144","volume":"138","author":"T Danne","year":"2013","unstructured":"Danne T, Kaltheuner M, Koch A et al (2013) \u201cDIabetes versorgungs-evaluation\u201d (DIVE)\u2014a national quality assurance initiative at physicians providing care for patients with diabetes. Dtsch Med Wochenschr 138:934\u2013939. \nhttps:\/\/doi.org\/10.1055\/s-0033-1343144","journal-title":"Dtsch Med Wochenschr"},{"key":"1409_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0169-2607(02)00035-4","volume":"69","author":"M Grabert","year":"2002","unstructured":"Grabert M, Schweiggert F, Holl RW (2002) A framework for diabetes documentation and quality management in Germany: 10\u00a0years of experience with DPV. Comput Methods Programs Biomed 69:115\u2013121","journal-title":"Comput Methods Programs Biomed"},{"key":"1409_CR6","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/clinchem\/33.12.2267","volume":"33","author":"DCCT Research Group","year":"1987","unstructured":"DCCT Research Group (1987) Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem 33:2267\u20132271","journal-title":"Clin Chem"},{"key":"1409_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2337\/dc11-0993","volume":"35","author":"J Rosenbauer","year":"2012","unstructured":"Rosenbauer J, Dost A, Karges B et al (2012) Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care 35:80\u201386. \nhttps:\/\/doi.org\/10.2337\/dc11-0993","journal-title":"Diabetes Care"},{"key":"1409_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.diabres.2016.03.008","volume":"115","author":"B Bohn","year":"2016","unstructured":"Bohn B, Kerner W, Seufert J et al (2016) Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract 115:31\u201338. \nhttps:\/\/doi.org\/10.1016\/j.diabres.2016.03.008","journal-title":"Diabetes Res Clin Pract"},{"key":"1409_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"Workgroup on Hypoglycemia ADA","year":"2005","unstructured":"Workgroup on Hypoglycemia ADA (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245\u20131249. \nhttps:\/\/doi.org\/10.2337\/diacare.28.5.1245","journal-title":"Diabetes Care"},{"key":"1409_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105\u2013113. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(17)30412-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"302","key":"1409_CR11","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.amjmed.2011.07.033","volume":"125","author":"NR Desai","year":"2012","unstructured":"Desai NR, Shrank WH, Fischer MA et al (2012) Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125(302):e301\u2013e307. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2011.07.033","journal-title":"Am J Med"},{"key":"1409_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2337\/dc16-1943","volume":"40","author":"L Azoulay","year":"2017","unstructured":"Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40:706\u2013714. \nhttps:\/\/doi.org\/10.2337\/dc16-1943","journal-title":"Diabetes Care"},{"key":"1409_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","volume":"56","author":"JA Hirst","year":"2013","unstructured":"Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ (2013) Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 56:973\u2013984. \nhttps:\/\/doi.org\/10.1007\/s00125-013-2856-6","journal-title":"Diabetologia"},{"key":"1409_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2337\/dc13-1901","volume":"37","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT (2014) Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care 37:1338\u20131345. \nhttps:\/\/doi.org\/10.2337\/dc13-1901","journal-title":"Diabetes Care"},{"key":"1409_CR15","unstructured":"(2013) Canaglifozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 55:37\u201339"},{"key":"1409_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00592-015-0794-0","volume":"52","author":"B Hartmann","year":"2015","unstructured":"Hartmann B, Bramlage P, Schneider S, Tschope D, Gitt AK (2015) Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort. Acta Diabetol 52:1093\u20131101. \nhttps:\/\/doi.org\/10.1007\/s00592-015-0794-0","journal-title":"Acta Diabetol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01409-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:53:34Z","timestamp":1598658814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01409-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01409-3","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"type":"print","value":"0940-5429"},{"type":"electronic","value":"1432-5233"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS reports grants and personal fees from Abbott, AstraZeneca and Sanofi, outside the submitted work. PB reports to have received consultancy honoraria from Sanofi and Abbott. BH, SL, GvM, FJW, MD, MP and SS have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The registry was conducted in accordance with Good Epidemiology Practice and applicable regulatory requirements. The protocol of DIVE registry was approved by the ethics committee of the Medical School of Hannover (approval no. 6003), the protocol of DPV was approved by the ethics committee of the University of Ulm (approval no. 202\/09), and data collection was approved by local review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All patients being enrolled into this registry provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}